MétaCan
Menu
← Back to cohort
Record W2792603554 · doi:10.1093/jcag/gwy009.175

A175 LINACLOTIDE AND PRUCALOPRIDE FOR MANAGEMENT OF CONSTIPATION IN PATIENTS WITH PARKINSONISM.

2018· article· en· W2792603554 on OpenAlexaff
Maria Eliza Freitas, Abdullah Alqaraawi, Arnold Lang, Lang Liu

Bibliographic record

VenueJournal of the Canadian Association of Gastroenterology · 2018
Typearticle
Languageen
FieldMedicine
TopicParkinson's Disease Mechanisms and Treatments
Canadian institutionsUniversity Health NetworkToronto Western HospitalUniversity of Toronto
Fundersnot available
KeywordsMedicineParkinsonismInternal medicineConstipationGastroenterologyPopulationDisease

Abstract

fetched live from OpenAlex

Constipation is a common condition in patients with neurodegenerative parkinsonism, including Parkinson’s disease (PD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP). Chronic constipation negatively impacts quality of life and decrease the absorption of antiparkinsonian drugs. Linaclotide (guanylate cyclase C agonist) and prucalopride (selective 5-HT4 receptor agonist) are emerging effective drugs for the management of chronic idiopathic constipation (CIC). To date, neither of these drugs has been tested in controlled trials in parkinsonism patients and their efficacy is unknown in this population. We aimed to identify patients who received linaclotide or prucalopride in our clinic database and to review the change in bowel movement frequency and the patient perception of drug effect. We searched our patient database for patients diagnosed with neurodegenerative parkinsonism and constipation who had received linaclotide or prucalopride. Constipation was defined by Rome III criteria. Demographics, treatment characteristics, BM frequency, side effects were captured from medical records. Objective improvement was defined as post-treatment BM frequency of 3 or more per week. Subjective improvement was assessed by clinical or telephone interview and defined as agreement or strong agreement in a 5-point Likert scale. Continuous variables were expressed as median[range] or mean±SD (Wilcoxon signed-rank or Fisher’s exact test). Among the 31 patients identified, 13 patients received linaclotide, 11 received prucalopride, and 7 individuals initially received prucalopride, which was switched to linaclotide. The number of BM per week significantly increased after treatment with either linaclotide (1[1–3] vs. 3.5[2–7]; p<0.05) or prucalopride (1[1–2] vs. 5[1–7]; p<0.05). In patients who did not respond to prucalopride, 71.4% reported improvement after switching to linaclotide. Both drugs improved the BM frequency in our patients with neurodegenerative parkinsonism who had failed initial constipation management. Interestingly, a higher proportion of patients reported subjective satisfaction in controlling their constipation symptoms with the use of linaclotide as compared with prucalopride. Our preliminary results suggested potential benefits of these medications, thus should encourage further well-designed controlled trials to advance the standard of care of constipation in patients with parkinsonism. None

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.009
Threshold uncertainty score0.029

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0090.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.006
GPT teacher head0.220
Teacher spread0.214 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2018
Admission routes1
Has abstractyes

Explore more

Same venueJournal of the Canadian Association of Gastroenterology→Same topicParkinson's Disease Mechanisms and Treatments→French-language works237,207→